The renaissance of polypharmacology in the development of anti-cancer therapeutics: Inhibition of the "triad of Death" in cancer by Di-2-pyridylketone thiosemicarbazones

Pharmacological Research

Volumn 100, Issue , 2015, Pages 255-260

  Jansson, Patric J ^a   Kalinowski, Danuta S ^a   Lane, Darius J R ^a   Kovacevic, Zaklina ^a   Seebacher, Nicole A ^a   Fouani, Leyla ^a   Sahni, Sumit ^a   Merlot, Angelica M ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

DpC; Metastasis; Polypharmacology; Resistance; Thiosemicarbazones; Tumor growth

Indexed keywords

ANTHRACYCLINE; CYCLIN D1; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DI 2 PYRIDYLKETONE THIOSEMICARBAZONE DERIVATIVE; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE; MYOSIN LIGHT CHAIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RIBONUCLEOTIDE REDUCTASE; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; THIOSEMICARBAZONE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PTEN PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; CATALYSIS; CELL CYCLE G1 PHASE; CELL PROLIFERATION; DNA SYNTHESIS; DOWN REGULATION; DRUG POTENCY; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IRON CHELATION; LUNG CARCINOMA; NONHUMAN; OXIDATION REDUCTION REACTION; PHENOTYPE; POLYPHARMACOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; HUMANS; POLYPHARMACOLOGY; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; THIOSEMICARBAZONES; UP-REGULATION;

EID: 84940832025     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.08.013     Document Type: Article

References (83)

1. A.S. Reddy, and S. Zhang Polypharmacology drug discovery for the future Expert. Rev. Clin. Pharmacol. 6 1 2013 41 47
2. Y. Hu, and J. Bajorath Compound promiscuity: what can we learn from current data? Drug Discov. Today 18 13-14 2013 644 650
3. M. Greaves, and C.C. Maley Clonal evolution in cancer Nature 481 7381 2012 306 313
4. S. Hess The emerging field of chemo- and pharmacoproteomics Proteom. Clin. Appl. 7 1-2 2013 171 180
5. A.L. Hopkins Network pharmacology: the next paradigm in drug discovery Nat. Chem. Biol. 4 11 2008 682 690
6. A.D. Boran, and R. Iyengar Systems approaches to polypharmacology and drug discovery Curr. Opin. Drug Discov. Dev. 13 3 2010 297 309
7. J.U. Peters Polypharmacology - foe or friend? J. Med. Chem. 56 22 2013 8955 8971
8. G. Bottegoni, A.D. Favia, M. Recanatini, and A. Cavalli The role of fragment-based and computational methods in polypharmacology Drug Discov. Today 17 1-2 2012 23 34
9. D.S. Kalinowski, and D.R. Richardson The evolution of iron chelators for the treatment of iron overload disease and cancer Pharmacol. Rev. 57 4 2005 547 583
10. J.L. Buss, F.M. Torti, and S.V. Torti The role of iron chelation in cancer therapy Curr. Med. Chem. 10 12 2003 1021 1034
11. K. Daniel, P. Gupta, R. Harbach, W.C. Guida, and Q.P. Dou Organic Cu complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells Biochem. Pharmacol. 67 6 2004 1139 1151
12. A. Gupte, and R. Mumper Elevated copper and oxidative stress in cancer cells Cancer Treat. Rev. 35 1 2009 32 46
13. D.S. Kalinowski, P. Quach, and D.R. Richardson Thiosemicarbazones the new wave in cancer treatment Future Med. Chem. 1 6 2009 1143 1151
14. M. Whitnall, J. Howard, P. Ponka, and D.R. Richardson A class of iron chelators with a wide spectrum of potent anti-tumor activity that overcome resistance to chemotherapeutics Proc. Natl. Acad. Sci. U. S. A. 103 2006 14901 14906
15. S. Ishida, P. Andreux, C. Poitry-Yamate, J. Auwerx, and D. Hanahan Bioavailable copper modulates oxidative phosphorylation and growth of tumors Proc. Natl. Acad. Sci. U. S. A. 110 2013 19507 19512
16. S. Ishida, F. McCormick, K. Smith-McCune, and D. Hanahan Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator Cancer Cell 17 6 2010 574 583
17. J. Yuan, D.B. Lovejoy, and D.R. Richardson Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity Blood 104 5 2004 1450 1458
18. P.V. Bernhardt, P.C. Sharpe, M. Islam, D.B. Lovejoy, D.S. Kalinowski, and D.R. Richardson Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity J. Med. Chem. 52 2 2009 407 415
19. D.S. Kalinowski, P.C. Sharpe, P.V. Bernhardt, and D.R. Richardson Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues J. Med. Chem. 50 24 2007 6212 6225
20. D.S. Kalinowski, Y. Yu, P.C. Sharpe, M. Islam, Y.T. Liao, D.B. Lovejoy, N. Kumar, P.V. Bernhardt, and D.R. Richardson Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents J. Med. Chem. 50 15 2007 3716 3729
21. D.R. Richardson, D.S. Kalinowski, V. Richardson, P.C. Sharpe, D.B. Lovejoy, M. Islam, and P.V. Bernhardt 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents J. Med. Chem. 52 5 2009 1459 1470
22. D. Richardson, P. Sharpe, D. Lovejoy, D. Senaratne, D.S. Kalinowski, M. Islam, and P.V. Bernhardt Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity J. Med. Chem. 49 22 2006 6510 6521
23. Z. Kovacevic, S. Chikhani, D. Lovejoy, and D.R. Richardson Novel thiosemicarbazones induce up-regulation and phosphorylation of the metastasis suppressor NDRG1 Mol. Pharmacol. 80 4 2011 598 609
24. Y. Yu, Y. Suryo Rahmanto, and D.R. Richardson Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy Br. J. Pharmacol. 165 1 2012 148 166
25. D.B. Lovejoy, D.M. Sharp, N. Seebacher, P. Obeidy, T. Prichard, C. Stefani, M.T. Basha, P.C. Sharpe, P.J. Jansson, D.S. Kalinowski, P.V. Bernhardt, and D.R. Richardson Novel second-generation di-2-pyridylketone thiosemicarbazones J. Med. Chem. 55 16 2012 7230 7244
26. D.S. Kalinowski, and D.R. Richardson Future of toxicology-iron chelators and differing modes of action and toxicity: the changing face of iron chelation therapy Chem. Res. Toxicol. 20 5 2007 715 720
27. D. Lovejoy, P. Jansson, U.T. Brunk, J. Wong, P. Ponka, and D.R. Richardson Antitumor activity of metal-chelating compound Dp44mT Cancer Res. 71 17 2011 5871 5880
28. R.A. Finch, M.C. Liu, A.H. Cory, J.G. Cory, and A.C. Sartorelli Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity Adv. Enzyme Regul. 39 1999 3 12
29. A.C. Sartorelli, K.C. Agrawal, A.S. Tsiftsoglou, and E.C. Moore Characterization of the biochemical mechanism of action of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones Adv. Enzyme Regul. 15 1976 117 139
30. G. Darnell, and D.R. Richardson The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation Blood 94 2 1999 781 792
31. D. Fu, and D.R. Richardson Iron chelation and regulation of the cell cycle: 2 mechanisms of posttranscriptional regulation of the universal cyclin-dependent kinase inhibitor p21CIP1/WAF1 by iron depletion Blood 110 2 2007 752 761
32. K.S. Kulp, S.L. Green, and P.R. Vulliet Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells Exp. Cell Res. 229 1 1996 60 68
33. J. Gao, and D.R. Richardson The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents, IV: the mechanisms involved in inhibiting cell-cycle progression Blood 98 3 2001 842 850
34. E. Nurtjahja-Tjendraputra, D. Fu, J.M. Phang, and D.R. Richardson Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression Blood 109 9 2007 4045 4054
35. E. Noulsri, D.R. Richardson, S. Lerdwana, S. Fucharoen, T. Yamagishi, D.S. Kalinowski, and K. Pattanapanyasat Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells Am. J. Hematol. 84 3 2009 170 176
36. R. Moussa, Z. Kovacevic, and D.R. Richardson Differential targeting of the cyclin-dependent kinase inhibitor, p21cip1/waf1, by chelators with anti-proliferative activity in a range of tumor cell-types Oncotarget 2015 in press 28/7/2015
37. K. Dixon, G. Lui, Z. Kovacevic, D. Zhang, M. Yao, Z. Chen, Q. Dong, S. Assinder, and D. Richardson Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells Br. J. Cancer 108 2 2013 409 419
38. Z. Kovacevic, S. Chikhani, G.Y.L. Lui, S. Sivagurunathan, and D.R. Richardson The iron-regulated metastasis suppressor NDRG1 targets NEDD4L, PTEN and SMAD4 and inhibits the PI3K and Ras signaling pathways Antioxid. Redox Signal. 18 8 2013 874 887
39. Y. Yu, and D.R. Richardson Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1 J. Biol. Chem. 286 17 2011 15413 15427
40. G.Y. Lui, Z. Kovacevic, S.V. Menezes, D.S. Kalinowski, A.M. Merlot, S. Sahni, and D.R. Richardson Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion Mol. Pharmacol. 87 3 2015 543 560
41. W. Liu, F. Yue, M. Zheng, A. Merlot, D.H. Bae, M. Huang, D. Lane, P. Jansson, G.Y. Lui, V. Richardson, S. Sahni, D. Kalinowski, Z. Kovacevic, and D.R. Richardson The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1 Oncotarget 6 11 2015 8851 8874
42. J. Sun, D. Zhang, Y. Zheng, Q. Zhao, M. Zheng, Z. Kovacevic, and D.R. Richardson Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway Mol. Pharmacol. 83 2 2013 454 469
43. G.Y. Lui, Z. Kovacevic, V. Richardson, A.M. Merlot, D.S. Kalinowski, and D.R. Richardson Targeting cancer by binding iron: dissecting cellular signaling pathways Oncotarget 2015 PMID. 26125440
44. E. Gutierrez, D.R. Richardson, and P.J. Jansson The anticancer agent di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes prosurvival autophagy by two mechanisms: persistent induction of autophagosome synthesis and impairment of lysosomal integrity J. Biol. Chem. 289 48 2014 33568 33589
45. S. Sahni, D.H. Bae, D.J. Lane, Z. Kovacevic, D.S. Kalinowski, P.J. Jansson, and D.R. Richardson The metastasis suppressor, N-myc downstream regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells J. Biol. Chem. 289 14 2014 9692 9709
46. Z. Chen, D. Zhang, F. Yue, M. Zheng, Z. Kovacevic, and D.R. Richardson The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-myc downstream-regulated gene 1 (NDRG1) J. Biol. Chem. 287 21 2012 17016 17028
47. D.J. Lane, T.M. Mills, N.H. Shafie, A.M. Merlot, R. Saleh Moussa, D.S. Kalinowski, Z. Kovacevic, and D.R. Richardson Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition Biochim. Biophys. Acta 1845 2 2014 166 181
48. J. Wang, D. Yin, C. Xie, T. Zheng, Y. Liang, X. Hong, Z. Lu, X. Song, R. Song, H. Yang, B. Sun, N. Bhatta, X. Meng, S. Pan, H. Jiang, and L. Liu The iron chelator Dp44mT inhibits hepatocellular carcinoma metastasis via N-myc downstream-regulated gene 2 (NDRG2)/gp130/STAT3 pathway Oncotarget 5 18 2014 8478 8491
49. W. Liu, F. Xing, M. Iiizumi-Gairani, H. Okuda, M. Watabe, S.K. Pai, P.R. Pandey, S. Hirota, A. Kobayashi, Y.Y. Mo, K. Fukuda, Y. Li, and K. Watabe N-Myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis EMBO Mol. Med. 4 2 2012 93 108
50. V.A. Rao, S.R. Klein, K.K. Agama, E. Toyoda, N. Adachi, Y. Pommier, and E.B. Shacter The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells Cancer Res. 69 3 2009 948 957
51. A. Gaal, G. Orgovan, Z. Polgari, A. Reti, V.G. Mihucz, S. Bosze, N. Szoboszlai, and C. Streli Complex forming competition and in-vitro toxicity studies on the applicability of di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT) as a metal chelator J. Inorg. Biochem. 130 2014 52 58
52. K. Ishiguro, Z.P. Lin, P.G. Penketh, K. Shyam, R. Zhu, R.P. Baumann, Y.L. Zhu, A.C. Sartorelli, T.J. Rutherford, and E.S. Ratner Distinct mechanisms of cell-kill by triapine and its terminally dimethylated derivative Dp44mT due to a loss or gain of activity of their copper(II) complexes Biochem. Pharmacol. 91 3 2014 312 322
53. A.M. Merlot, D.S. Kalinowski, and D.R. Richardson Novel chelators for cancer treatment: where are we now? Antioxid. Redox Signal. 18 8 2013 973 1006
54. C.F. Higgins Multiple molecular mechanisms for multidrug resistance transporters Nature 446 7137 2007 749 757
55. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 5 2003 411 424
56. T.B. Chaston, and D.R. Richardson Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity Am. J. Hematol. 73 3 2003 200 210
57. P.J. Jansson, P.C. Sharpe, P.V. Bernhardt, and D.R. Richardson Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity J. Med. Chem. 53 15 2010 5759 5769
58. P.J. Jansson, C.L. Hawkins, D.B. Lovejoy, and D.R. Richardson The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study J. Inorg. Biochem. 104 11 2010 1224 1228
59. T. Kurz, A. Terman, B. Gustafsson, and U.T. Brunk Lysosomes in iron metabolism, ageing and apoptosis Histochem. Cell Biol. 129 4 2008 389 406
60. P.J. Jansson, T. Yamagishi, A. Arvind, N. Seebacher, E. Gutierrez, A. Stacy, S. Maleki, D. Sharp, S. Sahni, and D.R. Richardson Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp) J. Biol. Chem. 290 15 2015 9588 9603
61. T. Yamagishi, S. Sahni, D.M. Sharp, A. Arvind, P.J. Jansson, and D.R. Richardson P-Glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration J. Biol. Chem. 288 44 2013 31761 31771
62. K. Tsuchihara, S. Fujii, and H. Esumi Autophagy and cancer: dynamism of the metabolism of tumor cells and tissues Cancer Lett. 278 2 2009 130 138
63. S. Sahni, A.M. Merlot, S. Krishan, P.J. Jansson, and D.R. Richardson Gene of the month: BECN1 J. Clin. Pathol. 67 8 2014 656 660
64. C.M. Kenific, A. Thorburn, and J. Debnath Autophagy and metastasis: another double-edged sword Curr. Opin. Cell Biol. 22 2 2010 241 245
65. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 5 2011 646 674
66. B.A. Fang, Z. Kovacevic, K.C. Park, D.S. Kalinowski, P.J. Jansson, D.J. Lane, S. Sahni, and D.R. Richardson Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy Biochim. Biophys. Acta 1845 1 2014 1 19
67. J. Sun, D. Zhang, D.H. Bae, S. Sahni, P. Jansson, Y. Zheng, Q. Zhao, F. Yue, M. Zheng, Z. Kovacevic, and D.R. Richardson Metastasis suppressor, NDRG1, mediates its activity through signaling pathways and molecular motors Carcinogenesis 34 9 2013 1943 1954
68. Z. Kovacevic, and D.R. Richardson The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer Carcinogenesis 27 12 2006 2355 2366
69. Y. Maruyama, M. Ono, A. Kawahara, T. Yokoyama, Y. Basaki, M. Kage, S. Aoyagi, H. Kinoshita, and M. Kuwano Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis Cancer Res. 66 12 2006 6233 6242
70. D.-H. Bae, P.J. Jansson, M.L. Huang, Z. Kovacevic, D. Kalinowski, C.S. Lee, S. Sahni, and D.R. Richardson The role of NDRG1 in the pathology and potential treatment of human cancers J. Clin. Pathol. 66 11 2013 911 917
71. S. Bandyopadhyay, S.K. Pai, S.C. Gross, S. Hirota, S. Hosobe, K. Miura, K. Saito, T. Commes, S. Hayashi, and M. Watabe The Drg-1 gene suppresses tumor metastasis in prostate cancer Cancer Res. 63 8 2003 1731 1736
72. S. Bandyopadhyay, S.K. Pai, S. Hirota, S. Hosobe, Y. Takano, K. Saito, D. Piquemal, T. Commes, M. Watabe, and S.C. Gross Role of the putative tumor metastasis suppressor gene Drg-1 in breast cancer progression Oncogene 23 33 2004 5675 5681
73. R.J. Guan, H.L. Ford, Y. Fu, Y. Li, L.M. Shaw, and A.B. Pardee Drg-1 as a differentiation-related, putative metastatic suppressor gene in human colon cancer Cancer Res. 60 3 2000 749 755
74. J.R. Hickok, S. Sahni, Y. Mikhed, M.G. Bonini, and D.D. Thomas Nitric oxide suppresses tumor cell migration through N-Myc downstream-regulated gene-1 (NDRG1) expression: role of chelatable iron J. Biol. Chem. 286 48 2011 41413 41424
75. M.A. Shah, N. Kemeny, A. Hummer, M. Drobnjak, M. Motwani, C. Cordon-Cardo, M. Gonen, and G.K. Schwartz Drg1 expression in 131 colorectal liver metastases: correlation with clinical variables and patient outcomes Clin. Cancer Res. 11 9 2005 3296 3302
76. W. Liu, Z. Kovacevic, R. Jin, P. Wang, F. Yue, M. Zheng, M.L.H. Huang, P.J. Jansson, V. Richardson, D.S. Kalinowski, D.J.R. Lane, A.M. Merlot, S. Sahni, and D.R. Richardson The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets Oncotarget 6 10 2015 8851 8874
77. E. Angst, S. Sibold, C. Tiffon, R. Weimann, B. Gloor, D. Candinas, and D. Stroka Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer Br. J. Cancer 95 3 2006 307 313
78. B. Chen, D.M. Nelson, and Y. Sadovsky N-Myc down-regulated gene 1 modulates the response of term human trophoblasts to hypoxic injury J. Biol. Chem. 281 5 2006 2764 2772
79. K. Kokame, H. Kato, and T. Miyata Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis GRP78/BiP and novel genes J. Biol. Chem. 271 47 1996 29659 29665
80. N.T. Le, and D.R. Richardson Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation Blood 104 9 2004 2967 2975
81. K. Salnikow, M.V. Blagosklonny, H. Ryan, R. Johnson, and M. Costa Carcinogenic nickel induces genes involved with hypoxic stress Cancer Res. 60 1 2000 38 41
82. Z. Kovacevic, D. Fu, and D.R. Richardson The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets Biochim. Biophys. Acta 1783 10 2008 1981 1992
83. D.J. Lane, F. Saletta, Y.S. Rahmanto, Z. Kovacevic, and D.R. Richardson N-Myc downstream regulated 1 (NDRG1) is regulated by eukaryotic initiation factor 3a (eIF3a) during cellular stress caused by iron depletion PLoS One 8 2 2013 e57273